A noninvasive ultrasound device restored heart rhythm in animal models and engineered human heart cells, paving the way for ...

Patients increasingly come to visits with AI-generated ideas and online research, forcing doctors to balance information, ...

Antiamyloid drugs clear amyloid plaques and modestly slow cognitive decline in patients with Alzheimer’s disease, but whether ...

An imaging-derived muscle-fat index predicts heart failure, cardiovascular deaths, and all-cause deaths more accurately than BMI and waist-based measures.

In Canada, ED overcrowding, particularly with older adults, is a healthcare system failure that must be addressed across ...

The EMA has alerted healthcare professionals to a small increased risk for meningioma with the progestogen-based contraceptives desogestrel and etonogestrel.

A network meta-analysis of 19 weight-loss drugs concludes that most obesity drugs don’t improve quality of life or cardiovascular health.

New data suggest an approach that could improve the use of guideline-directed medical therapy among patients with heart ...

The DEA’s proposal would classify concentrated synthetic 7-OH products as Schedule I drugs, while leaving most botanical kratom outside the ban.

AI-based computer-aided detection devices during colonoscopy was associated with higher adenoma detection rates than usual ...

Fascinating nervous system imaging reveals previously unseen obesity-related nerve damage in mice and humans — and some of it ...

Roflumilast 0.05% (Zoryve), a topical phosphodiesterase-4 inhibitor, is currently approved for treating mild-to-moderate AD in children aged 2 years or older; it was approved for ...